Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Lessened by Guggenheim Capital LLC

Guggenheim Capital LLC decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 34.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,699 shares of the medical equipment provider's stock after selling 8,433 shares during the quarter. Guggenheim Capital LLC's holdings in Lantheus were worth $1,404,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Lantheus in the 4th quarter valued at approximately $36,183,000. Swedbank AB raised its holdings in shares of Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after acquiring an additional 385,000 shares during the last quarter. Keybank National Association OH purchased a new stake in shares of Lantheus in the fourth quarter valued at $27,526,000. Norges Bank acquired a new stake in shares of Lantheus during the fourth quarter valued at $26,189,000. Finally, Wellington Management Group LLP purchased a new stake in Lantheus during the 4th quarter worth about $20,022,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JMP Securities restated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Finally, B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average target price of $129.43.

Insider Activity at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 63,109 shares of company stock worth $6,016,046. Corporate insiders own 2.00% of the company's stock.

Lantheus Price Performance

NASDAQ:LNTH traded down $1.87 during trading hours on Friday, reaching $101.77. 644,509 shares of the company were exchanged, compared to its average volume of 952,288. The firm has a market cap of $6.97 billion, a price-to-earnings ratio of 16.93 and a beta of 0.20. The stock has a 50 day simple moving average of $97.01 and a 200 day simple moving average of $95.38. Lantheus Holdings, Inc. has a 52-week low of $63.76 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.